Latest news with #ErisLifesciences
&w=3840&q=100)
Business Standard
20-05-2025
- Business
- Business Standard
Eris Lifesciences rises 4% on posting Q4 results; Check all details here
Eris Lifesciences share price gained 4.2 per cent in trade, logging an intraday high at ₹1,504.5 per share on BSE. The buying on the counter came after the company posted its Q4 results. However, At 12:40 PM, Eris Lifesciences shares pared some gains and were up 0.94 per cent at ₹1,457 per share on the BSE. In comparison, the BSE Sensex was down 0.38 per cent at 81,746.76. The market capitalisation of the company stood at ₹219,842.16 crore. The 52-week high of the stock was at ₹1,593 per share and the 52-week low of the stock was at ₹815.5 per share. Eris Lifesciences results The company released its fourth quarter (Q4FY25) results on Monday, after market hours. The consolidated net profit for the quarter stood at ₹102 crore as compared to ₹80 crore year-on-year (Y-o-Y), rising 28 per cent. The company's revenue from operations in Q4 stood at ₹705 crore as against ₹551 crore a year ago, up 28 per cent. The company's Earnings before interest, tax, depreciation and amortisation (Ebitda) for the quarter stood at ₹252 crore as compared to ₹148 crore a year ago. The Ebitda margin for Q4 stood at 35.8 per cent as against 26.9 per cent. ALSO READ | About Eris Lifesciences Eris Lifesciences is an Indian pharmaceutical company and a player in the domestic branded formulations market. Eris has established a leading presence in its core cardio-metabolic franchise just 17 years from inception. The company embarked on a remarkable journey in the Indian pharmaceutical industry 17 years ago, driven by a vision to make a meaningful impact in the management of chronic diseases and build a business model pivoted around specialist and super-specialist doctors. The company focuses on engagement programmes aimed at facilitating the generation of actionable scientific evidence to enable clinicians to improve clinical outcomes as well as augmenting our Patient Care Initiatives by bringing diagnostic facilities and subsequent treatment options.
Business Standard
20-05-2025
- Business
- Business Standard
Eris Lifesciences gains after Q4 PAT climbs 32% YoY to Rs 94 cr
Eris Lifesciences added 1.22% to Rs 1,461 after the company's consolidated net profit jumped 32.1% to Rs 93.84 crore on 28.4% increase in revenue from operations to Rs 702.60 crore in Q4 FY25 over Q4 FY24. Profit before tax (PBT) climbed 67.9% YoY to Rs 128.87 crore in Q4 FY25. During the quarter EBITDA stood at Rs 252 crore, up 70% compared with Rs 148 crore posted in same quarter last year. EBITDA margin expanded to 35.8% in Q4 FY25 as against 26.9% in Q4 FY24. Revenue from domestic branded formulation (DBF) business jumped 25% YoY to Rs 602 crore in Q4 FY25. The organic base grew 10% to Rs 529 crore, while revenue from Biocon -2 stood at Rs 73 crore during the period under review. The company reported 22% organic growth in overall insulin revenue to Rs 300 crore despite significant product shortage in RHI throughout the year. On full year basis, the companys consolidated net profit declined 10.3% to Rs 351.84 crore on 44.6% increase in revenue from operations to Rs 2,879.26 crore in FY25 over FY24. On guidance front, for FY26, the company projects an annual revenue addition of Rs 200300 crore to its overall insulin franchise, beginning October 2025, driven by the insourcing of insulin production at its Bhopal facility. This strategic move is expected to significantly enhance its insulin portfolio. In DBF business, the company anticipates revenue growth of 15% to 21%, translating to revenues in the range of Rs 2,9003,050 crore. EBITDA for the segment is projected between Rs 1,070 crore and Rs 1,130 crore, with EBITDA margins maintained around 37%. Additionally, the company expects revenues from its Swiss Parentals division to range between Rs 375- 390 crore reflecting a growth of 1520%. EBITDA for this segment is estimated between Rs 130 crore and Rs 135 crore, with an EBITDA margin of approximately 35%. The company plans to expand Eris-AMD, its new injectable facility, with a capital expenditure of Rs 100- 200 crore in FY26. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products.
Yahoo
20-05-2025
- Business
- Yahoo
Eris Lifesciences Ltd (NSE:ERIS) Q4 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ...
Release Date: May 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Eris Lifesciences Ltd (NSE:ERIS) reported a 28% year-on-year growth in consolidated operating revenue for Q4, reaching INR 705 crores. The company achieved a significant 70% year-on-year growth in consolidated EBITDA, amounting to INR 252 crores. Eris Lifesciences Ltd (NSE:ERIS) saw a 28% growth in profit after tax, totaling INR 102 crores for the quarter. The company reported a strong operating cash flow to EBITDA ratio of 111% in Q4. The return on capital employed (ROCE) improved to 15% for FY25, up from 11% in the previous year, with an adjusted ROCE of 20%. There was a significant product shortage in human insulin, resulting in an estimated sales loss of around INR 50 crores. The critical care segment experienced a planned 20% decline, attributed to delays in building out the domestic go-to-market strategy. The company faced challenges in the oncology business due to product mix issues, impacting performance. Insulin fill-in took longer than anticipated, affecting the rollout of certain products. The company experienced intermittent connection issues during the earnings call, leading to unclear communication at times. Warning! GuruFocus has detected 8 Warning Signs with NSE:ERIS. Q: Can you clarify the impact of the supply shortage on the insulin business and the expected market capture? A: We experienced a sales loss of around INR 50 crore due to supply shortages, with INR 38 crore within the Biocon One business. We are confident in capturing 50-60% of the vacated market, supported by a secured supply deal and upcoming capacity expansions. (Respondent: Unidentified_3) Q: What are the challenges faced in the critical care business, and how do you plan to address them? A: The critical care segment faced issues due to a lack of market strategy and bandwidth. We are working on improving our go-to-market strategy and expect to see improvements in the next quarter. (Respondent: Unidentified_3) Q: Why is there a discrepancy in the expected margin improvements despite significant growth in the insulin business? A: The expected margin improvements are tempered by the timing of cartridge production, which will start in Q4, and the addition of 300 new employees, which initially strains the EBITDA line. We are cautiously guiding a 37% margin. (Respondent: Unidentified_3) Q: How does Eris plan to fill the gap left by Novo's exit from the insulin cartridge market? A: We believe the substitutes offered by Novo are either reverting to vials or are significantly more expensive. We expect to capture a significant portion of the market due to our competitive pricing and established brands. (Respondent: Unidentified_3) Q: What are the next steps for Swiss Parentals in terms of export opportunities and CDMO contracts? A: We are awaiting N visa approval, which will open large markets for us. We are in discussions for CDMO contracts, focusing on specialty injectables for EU clients, with plans to expand into oral solids. (Respondent: Unidentified_3) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Business Upturn
20-05-2025
- Business
- Business Upturn
Eris Lifesciences shares jump 3% as Q4 EBITDA rises 69.8% YoY to 252.2 crore
By Aman Shukla Published on May 20, 2025, 09:28 IST Shares of Eris Lifesciences rose by around 3% in early trade following the release of the company's fourth-quarter earnings report. The pharmaceutical company posted a year-on-year increase in its net profit, revenue, and operating performance. As of 9:26 AM, the shares were trading 3.17% higher at Rs 1,489.40. The company's net profit for the quarter stood at ₹93.8 crore, marking an increase of 31.1% compared to the same period last year. Revenue for the quarter rose to ₹705 crore, up 27.9% from ₹551 crore in the corresponding quarter of the previous year. The company also posted an EBITDA of ₹252.2 crore, a rise of 69.8% on a year-on-year basis. Operating margins improved to 36% from 27% in the same period last year, indicating a more efficient cost structure and improved operational performance. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
